187 related articles for article (PubMed ID: 38803487)
1. Polish regulatory system regarding ATMP hospital exemptions.
Pachocki J; Verter F
Front Immunol; 2024; 15():1379134. PubMed ID: 38803487
[TBL] [Abstract][Full Text] [Related]
2. Patient access to and ethical considerations of the application of the European Union hospital exemption rule for advanced therapy medicinal products.
Cuende N; Ciccocioppo R; Forte M; Galipeau J; Ikonomou L; Levine BL; Srivastava A; Zettler PJ
Cytotherapy; 2022 Jul; 24(7):686-690. PubMed ID: 35545453
[TBL] [Abstract][Full Text] [Related]
3. An assessment of the hospital exemption landscape across European Member States: regulatory frameworks, use and impact.
Hills A; Awigena-Cook J; Genenz K; Ostertag M; Butler S; Eggimann AV; Hubert A
Cytotherapy; 2020 Dec; 22(12):772-779.e1. PubMed ID: 33046395
[TBL] [Abstract][Full Text] [Related]
4. Hurdles in clinical implementation of academic advanced therapy medicinal products: A national evaluation.
de Wilde S; Veltrop-Duits L; Hoozemans-Strik M; Ras T; Blom-Veenman J; Guchelaar HJ; Zandvliet M; Meij P
Cytotherapy; 2016 Jun; 18(6):797-805. PubMed ID: 27068764
[TBL] [Abstract][Full Text] [Related]
5. Advanced therapy medicinal product manufacturing under the hospital exemption and other exemption pathways in seven European Union countries.
Coppens DGM; Hoekman J; De Bruin ML; Slaper-Cortenbach ICM; Leufkens HGM; Meij P; Gardarsdottir H
Cytotherapy; 2020 Oct; 22(10):592-600. PubMed ID: 32563611
[TBL] [Abstract][Full Text] [Related]
6. Comparison of regulatory pathways for the approval of advanced therapies in the European Union and the United States.
Iglesias-Lopez C; Obach M; Vallano A; Agustí A
Cytotherapy; 2021 Mar; 23(3):261-274. PubMed ID: 33483292
[TBL] [Abstract][Full Text] [Related]
7. ATMP Environmental Exposure Assessment in European Healthcare Settings: A Systematic Review of the Literature.
Damerval M; Fagnoni-Legat C; Louvrier A; Fischer S; Limat S; Clairet AL; Nerich V; Madelaine I; Kroemer M
Front Med (Lausanne); 2021; 8():713047. PubMed ID: 34926483
[TBL] [Abstract][Full Text] [Related]
8. Call for More Effective Regulation of Clinical Trials with Advanced Therapy Medicinal Products Consisting of or Containing Genetically Modified Organisms in the European Union.
Beattie S;
Hum Gene Ther; 2021 Oct; 32(19-20):997-1003. PubMed ID: 33843251
[TBL] [Abstract][Full Text] [Related]
9. Unproven cell interventions in Poland and the exploitation of European Union law on advanced therapy medicinal products.
Dulak J; Pecyna M
Stem Cell Reports; 2023 Aug; 18(8):1610-1620. PubMed ID: 37390824
[TBL] [Abstract][Full Text] [Related]
10. Defining a Regulatory Strategy for ATMP/Aerosol Delivery Device Combinations in the Treatment of Respiratory Disease.
Woods N; MacLoughlin R
Pharmaceutics; 2020 Sep; 12(10):. PubMed ID: 32993197
[TBL] [Abstract][Full Text] [Related]
11. Advanced Therapy Medicinal Products and Exemptions to the Regulation 1394/2007: How Confident Can We be? An Exploratory Analysis.
Van Wilder P
Front Pharmacol; 2012; 3():12. PubMed ID: 22347860
[TBL] [Abstract][Full Text] [Related]
12. Marketing Regulatory Oversight of Advanced Therapy Medicinal Products in Europe.
Schuessler-Lenz M; Herberts C; Reischl I; Ruiz S; Celis P; Beuneu C; Kjeken R; Timón M
Adv Exp Med Biol; 2023; 1430():1-21. PubMed ID: 37526839
[TBL] [Abstract][Full Text] [Related]
13. Advanced Therapy Medicinal Products for Rare Diseases: State of Play of Incentives Supporting Development in Europe.
Farkas AM; Mariz S; Stoyanova-Beninska V; Celis P; Vamvakas S; Larsson K; Sepodes B
Front Med (Lausanne); 2017; 4():53. PubMed ID: 28560211
[TBL] [Abstract][Full Text] [Related]
14. Exploring Solutions to Foster ATMP Development and Access to Patients in Europe.
Salvatore V
Eur J Health Law; 2020 May; 27(3):259-273. PubMed ID: 33652396
[TBL] [Abstract][Full Text] [Related]
15. Cell therapy medicinal product regulatory framework in Europe and its application for MSC-based therapy development.
Ancans J
Front Immunol; 2012; 3():253. PubMed ID: 22912639
[TBL] [Abstract][Full Text] [Related]
16. Regulating advanced therapy medicinal products through the Hospital Exemption: an analysis of regulatory approaches in nine EU countries.
Coppens DG; Gardarsdottir H; Bruin ML; Meij P; Gm Leufkens H; Hoekman J
Regen Med; 2020 Aug; 15(8):2015-2028. PubMed ID: 33151792
[No Abstract] [Full Text] [Related]
17. Advanced Therapy Medicinal Products and the Changing Role of Academia.
Priesner C; Hildebrandt M
Transfus Med Hemother; 2022 Jun; 49(3):158-162. PubMed ID: 35813600
[TBL] [Abstract][Full Text] [Related]
18. Marketing Regulatory Oversight of Advanced Therapy Medicinal Products (ATMPs) in Europe: The EMA/CAT Perspective.
Salmikangas P; Schuessler-Lenz M; Ruiz S; Celis P; Reischl I; Menezes-Ferreira M; Flory E; Renner M; Ferry N
Adv Exp Med Biol; 2015; 871():103-30. PubMed ID: 26374215
[TBL] [Abstract][Full Text] [Related]
19. A Regulatory Risk-Based Approach to ATMP/CGT Development: Integrating Scientific Challenges With Current Regulatory Expectations.
Salazar-Fontana LI
Front Med (Lausanne); 2022; 9():855100. PubMed ID: 35646952
[TBL] [Abstract][Full Text] [Related]
20. The advanced therapy classification procedure. Overview of experience gained so far.
Voltz-Girolt C; Celis P; Boucaumont M; D'Apote L; Pinheiro MH; Papaluca-Amati M
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2011 Jul; 54(7):811-5. PubMed ID: 21698533
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
